Todd Skaar did his graduate work in nutrition at the University of Wisconsin, lactation physiology at the Penn State University, and a postdoc in breast cancer drug resistance at the Lombardi Cancer Center at Georgetown University. Since joining the Division of Clinical Pharmacology at the Indiana University School of Medicine, his research has focused on the discovery and implementation of genomic predictors of drug response. More specifically, his studies are focused on identifying and functionally testing genetic variants in the drug metabolism genes that are associated with clinical drug efficacy and toxicity. They also include studies to identify miRNAs that contribute to the drug-induced and developmental changes in hepatic drug metabolism. He co-leads multiple pharmacogenomics implementation clinical trials focused on identifying and overcoming the barriers to using pharmacogenomics to guide drug therapies. He is also a co-leader of the Cancer Prevention & Control Program of the Indiana University Cancer Center.
Phenoconversion is a phenomenon by which an individual’s genotype-predicted phenotype is transformed into another by factors such as drug interactions or diseases. This session will cover complexities of genotype result interpretation in clinical practice and clinical trials since phenoconversion makes challenging such translation of information into clinically actionable recommendations.